Patent Foramen Ovale

Publication Date: April 29, 2020

Key Points

Key Points

  • For patients with cryptogenic stroke and PFO, percutaneous PFO closure probably reduces the risk of stroke recurrence (HR-0.41, summary rate difference -0.67% per year), probably is associated with a periprocedural complication rate of 3.9%, and probably is associated with the development of serious non-periprocedural atrial fibrillation (RR-2.72, summary rate difference 0.33% per year).
  • For patients with cryptogenic stroke and PFO, anticoagulation medication and antiplatelet medication are possibly equally effective at reducing recurrent stroke.

Management

...agement

...ations Regarding Percutaneous PFO Closur...

...patients being considered for PFO closure, clini...

...g considered for PFO closure, clinic...

In patients being considered for PFO closure, cl...

...ents being considered for PFO closure, cl...

...ents being considered for PFO closure thought to b...

...ents being considered for PFO closure,...

...ts being considered for PFO closur...

...s being considered for PFO closure...

...g PFO closure, patients should be ass...

...higher risk alternative mechanism of st...

...going PFO closure, patients should be assesse...

...patients with a PFO detected after stroke...

...ounger than 60 years with a PFO and an embolic-app...

...ans may inform patients that presence of a large s...

PFO closure may be offered in othe...

...ay be offered to younger patients (e.g.,...

...t for whom PFO closure is being considered, a...


...dations Regarding Medical Therapy...

...who opt to receive medical therapy al...

...who would otherwise be considered good candidates...


...re 1. Management Algorithm...